

**Author Relationships With Industry and Other Entities (Comprehensive)—2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes (July 2013)**

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational or Other Financial Benefit	Expert Witness
Ezra A. Amsterdam ( <i>Chair</i> )	University of California (Davis) Medical Center, Division of Cardiology—Professor	None	None	None	<ul style="list-style-type: none"> <li>• California CABG Project</li> </ul>	<ul style="list-style-type: none"> <li>• American Journal of Cardiology†</li> <li>• Clinical Cardiology†</li> <li>• 2010 School of Medicine Research Award*</li> <li>• ACC-NCDR ACTION Registry Subcommittee - Research and Publications</li> </ul>	None
Nanette K. Wenger ( <i>Vice Chair</i> )	Emory University, School of Medicine—Professor of Medicine (Cardiology)	<ul style="list-style-type: none"> <li>• Abbott</li> <li>• Amgen</li> <li>• AstraZeneca</li> <li>• Gilead Sciences*</li> <li>• Janssen Pharmaceuticals</li> <li>• Medtronic</li> <li>• Merck</li> <li>• Pfizer</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Abbott*</li> <li>• Eli Lilly*</li> <li>• Gilead Sciences*</li> <li>• Merck</li> <li>• NHLBI*</li> <li>• Pfizer*</li> </ul>	<ul style="list-style-type: none"> <li>• ACC Extended Learning</li> <li>• CCOA</li> <li>• Clinical Cardiology Review Editor</li> <li>• Society for Women’s Health Research†</li> </ul>	None
Ralph G. Brindis	University of California, San Francisco—Department of Medicine and the Phillip R. Lee Institute for Health Policy Studies—Clinical Professor of Medicine	<ul style="list-style-type: none"> <li>• Ivivi Health Sciences</li> </ul>	<ul style="list-style-type: none"> <li>• Volcano Corp.</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• ACC-NCDR(Senior Medical Officer, External Affairs)</li> <li>• DAPT trial (Advisory Board)†</li> <li>• California State Elective PCI Project (Advisory Board)†</li> <li>• C-PORT Elective RCT† (DSMB)</li> <li>• FDA Cardiovascular Device Panel†</li> <li>• State of California</li> </ul>	None

						Health Dept: STEMI/PCI Work Group† (DSMB) • State of California OSHDP† (DSMB)	
Donald E. Casey, Jr	Atlantic Health—Vice President of Health and Chief Medical Officer	None	None	None	None	None	None
Theodore G. Ganiats	University of California, San Diego School of Medicine— Executive Director of Health Services Research Center	None	None	None	• AHRQ • NIH (DSMB)	None	• Plaintiff, deep vein thrombosis, 2011
David R. Holmes, Jr	Mayo Clinic— Consultant, Cardiovascular Diseases	None	None	None	None	• Atritech†	None
Allan S. Jaffe	Mayo Clinic, Cardiovascular Division—Professor of Medicine	• Abbott • Alere • Amgen • Beckman-Coulter • Critical Diagnostics • ET Healthcare • Ortho Clinical Diagnostic • Radiometer* • Roche† • Trinity • Thermo Fisher†	None	None	None	None	None
Hani Jneid	Baylor College of Medicine—The Michael E. DeBakey VA Medical Center— Assistant Professor of Medicine	None	None	None	None	None	None
Rosemary F. Kelly	University of Minnesota—Division	None	None	None	None	None	None

	of Cardiothoracic Surgery, Professor of Surgery						
Michael C. Kontos	Virginia Commonwealth University, Pauley Heart Center—Medical Director, Coronary Intensive Care Unit; Associate Professor, Internal Medicine	<ul style="list-style-type: none"> <li>• Astellas</li> <li>• General Electric</li> <li>• Ikaria</li> <li>• Prevencio</li> <li>• Quest Diagnostics</li> <li>• Sanofi-aventis</li> <li>• Wellpoint/Anthem</li> </ul>	<ul style="list-style-type: none"> <li>• Astellas</li> <li>• AstraZeneca</li> </ul>	None	<ul style="list-style-type: none"> <li>• Mission Lifeline Scientific Committee†</li> <li>• Society of Chest Pain Centers†</li> </ul>	<ul style="list-style-type: none"> <li>• AHA†</li> <li>• Astellas</li> <li>• Eli Lilly†</li> <li>• Merck †</li> <li>• NIH†</li> <li>• Novartis†</li> </ul>	<ul style="list-style-type: none"> <li>• Plaintiff, malpractice case with failure to treat properly, 2012</li> </ul>
Glenn N. Levine	Baylor College of Medicine—Professor of Medicine; Director, Cardiac Care Unit	None	None	None	None	None	None
Philip R. Liebson	Rush University Medical Center—McMullan-Eybel Chair of Excellence in Clinical Cardiology and Professor of Medicine and Preventive Medicine	None	None	None	None	None	None
Debabrata Mukherjee	Texas Tech University Health Sciences Center—Chief, Cardiovascular Medicine	None	None	None	None	None	None
Eric D. Peterson	Duke University Medical Center—Fred Cobb, MD, Distinguished Professor of Medicine; Duke Clinical Research Institute—Director	<ul style="list-style-type: none"> <li>• Boehringer Ingelheim</li> <li>• Genentech</li> <li>• Janssen Pharmaceuticals</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Eli Lilly*</li> <li>• Johnson &amp; Johnson*</li> <li>• Janssen Pharmaceuticals*</li> </ul>	<ul style="list-style-type: none"> <li>• DCRI‡</li> </ul>	None
Marc S. Sabatine	Brigham and Women's Hospital, Chairman—TIMI Study Group,	<ul style="list-style-type: none"> <li>• Aegerion</li> <li>• Amgen</li> <li>• AstraZeneca*</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Abbott*</li> <li>• Amgen*</li> <li>• AstraZeneca*</li> </ul>	<ul style="list-style-type: none"> <li>• AstraZeneca*</li> <li>• Athera Biotechnologies*</li> </ul>	None

	Division of Cardiovascular Medicine; Harvard Medical School—Professor of Medicine	<ul style="list-style-type: none"> <li>• Bristol-Myers Squibb</li> <li>• Canadian Cardiovascular Society</li> <li>• Creative Educational Concepts</li> <li>• Diasorin</li> <li>• GlaxoSmithKline</li> <li>• Health Sciences Media</li> <li>• Merck</li> <li>• Pfizer</li> <li>• Sanofi-aventis</li> <li>• Vertex</li> <li>• Vox Media</li> <li>• WebMD</li> </ul>			<ul style="list-style-type: none"> <li>• Bristol-Myers Squibb*</li> <li>• BRAHMS*</li> <li>• Critical Diagnostics*</li> <li>• Daiichi-Sankyo*</li> <li>• Eisai*</li> <li>• Genzyme*</li> <li>• GlaxoSmithKline*</li> <li>• Intarcia*</li> <li>• Nanosphere*</li> <li>• NIH*</li> <li>• Roche Diagnostics*</li> <li>• Sanofi-aventis*</li> <li>• Takeda*</li> </ul>	<ul style="list-style-type: none"> <li>• Daiichi-Sankyo*</li> <li>• Gilead*</li> <li>• GlaxoSmithKline*</li> <li>• Johnson &amp; Johnson*</li> <li>• Merck*</li> <li>• Muljibhai Patel Society for Research in Nepro-Urology*</li> <li>• Proventys*</li> <li>• Siemens*</li> <li>• Singulex*</li> </ul>	
Richard W. Smalling	University of Texas, Health Science Center at Houston—Professor and Director of Interventional Cardiovascular Medicine; James D. Woods Distinguished Chair in Cardiovascular Medicine	<ul style="list-style-type: none"> <li>• Gilead</li> <li>• St. Jude Medical</li> <li>• Maquet</li> <li>• Toshiba</li> </ul>	None	None	<ul style="list-style-type: none"> <li>• Amarin</li> <li>• Cordis</li> <li>• E-valve/Abbott Vascular</li> <li>• Gilead</li> <li>• St. Jude Medical</li> <li>• Maquet-Datascope</li> <li>• Edwards Lifesciences</li> </ul>	<ul style="list-style-type: none"> <li>• Cordis*</li> <li>• E-Valve*</li> <li>• St. Jude</li> </ul>	None
Susan J. Zieman	National Institute on Aging/NIH, Geriatrics Branch, Division of Geriatrics and Clinical Gerontology—Medical Officer	None	None	None	<ul style="list-style-type: none"> <li>• American Geriatrics Society†</li> <li>• AHA†</li> <li>• NIH*</li> </ul>	None	None

This table represents all healthcare relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of  $\geq 5\%$  of the voting stock or share of the business entity, or ownership of  $\geq \$10,000$  of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of

the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx> for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees.

\*Significant relationship.

†No financial benefit.

‡DCRI has numerous grants and contracts sponsored by industry. These include the following: Aastrom Biosciences; Abbott; Abiomed; Acom Cardiovascular; Adolor Corp; Advanced Cardiovascular Systems; Advanced Stent Technologies; Adynnx; Aijnomoto; Allergan; Amgen; Alnylam Pharma; Alpharma; Amylin Pharmaceuticals; Anadys; Anesiva; Angel Medical Systems; ANGES MG; Angiomedtrix; APT Nidus Center; ASCA Biopharma; Astellas Pharma; Asklepios; AstraZeneca; Atritech; Attention Therapeutics; Aventis; Baxter; Bayer; Berlex; BG Medicine; Biogen; Biolex Therapeutics; Biomarker Factory; Biosite; Boehringer Ingelheim Biogen; Boston Scientific; Bristol-Myers Squibb; BMS Pfizer; Carbomed; CardioDx; CardioKinetix; Cardiovascular Systems; Cardiovox; Celsion Corp; Centocor; Cerexa; Chase Medical; Conatus Pharmaceuticals; Conor Medsystems; Cortex; Corgentech; CSL Behring; CV Therapeutics; Daiichi Pharmaceuticals; Daiichi-Sankyo; Daiichi-Sankyo/Lilly; Dainippon; Datascope; Dendreon; Dr. Reddy's Laboratories; Eclipse Surgical Technologies; Edwards Lifesciences; Eisai; Endicor; EnteroMedics; Enzon Pharmaceuticals; Eli Lilly; Ethicon; Ev3; Evalve; F2G; Flow Cardia; Fox Hollow Pharmaceuticals; Fujisawa; Genetech; General Electric; General Electric Co.; General Electric Healthcare; General Electric Medical Systems; Genzyme Corp.; Genome Canada; Gilead Sciences; GlaxoSmithKline; Guidant Corp.; HeartScape Technologies; Hoffman-LaRoche; Hospira; Idera Pharmaceuticals; Ikaria; Incor Pharmaceuticals; Immunex; INFORMD; Inimex; Inspire Pharmaceuticals; Ischemix; Janssen; Johnson and Johnson; Jomed; Juventus Therapeutics; KAI Pharmaceuticals; King Pharmaceuticals; Kyowa Pharma; Luitpold; Mardil; MedImmune; Medscape; Medtronic Diabetes; Medtronic; Medtronic Vascular; Merck Group; MicroMed Technology; Millennium Pharmaceuticals; Mitsubishi Tanabe; Momenta; Nabriva; Neuron Pharmaceuticals; NitroMed; NovaCardia Inc; Novartis AG Group; Novartis Pharmaceuticals; Oncura; Orexigen; Ortho-McNeil-Janssen; OSI Eyetech; OSI Pharmaceuticals; Pfizer; Pharmacyclics; Pharmasset; Pharms; Phyxius Pharmaceuticals; Pharsight; Pluristen Therapeutics; Portola Pharmaceuticals; Proventys; Radiant; Regado Biosciences; Rengeneron Pharmaceuticals; Roche Molecular Systems; Roche Group; Roche Diagnostic; Salix Pharmaceuticals; Sanofi-Pasteur; Sanofi-aventis; Santaris Pharmaceuticals; Schering-Plough; Scios; Siemens; Southwest Oncology Group; Spectranetics; Summit; Sunovion Pharmaceuticals; TAP Pharmaceutical Products; Tengion; The Medicines Company; Theravance; TherOx; Tethys Bioscience; Theregen; Three Rivers Pharmaceuticals; The EMMES Corporation; UCB; Valentis; Valleylab; Vertex; Viacor; and Wyeth.

ACC indicates American College of Cardiology; AHA, American Heart Association; AHRQ, Agency for Healthcare Research and Quality; CABG, coronary artery bypass graft; CCCOA, Council on Cardiovascular Care for Older Adults; C-PORT, Cardiovascular Patient Outcomes Research Team; DAPT, dual antiplatelet therapy; DCRI, Duke Clinical Research Institute; DSMB, data safety monitoring board; FDA, Food and Drug Administration; MI, myocardial infarction; NCDR, National Cardiovascular Data Registry; NIH, National Institutes of Health; NHLBI, National Heart, Lung, and Blood Institute; OSHPD, Office of Statewide Health Planning and Development; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; STEMI, ST-elevation myocardial infarction; TIMI, Thrombolysis In Myocardial Infarction; and VA, Veterans Affairs.